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  42 
Preeclampsia, which affects approximately 5% of pregnancies, is a leading cause of maternal and 43 
perinatal death1.  The causes of preeclampsia remain unclear, but there is evidence for inherited 44 
susceptibility2.  Genome-wide association studies (GWAS) have not identified maternal sequence 45 
variants of genome-wide significance which replicate in independent datasets3,4.  We report the 46 
first GWAS of offspring of preeclamptic pregnancies and discovery of the first genome-wide 47 
significant susceptibility locus (rs4769613; P = 5.4x10-11) in 4380 cases and 310,238 controls. The 48 
locus is near the gene encoding Fms-like tyrosine kinase 1 (FLT1), providing biological support 49 
since an isoform (sFlt-1) of placental origin is implicated in the pathology of preeclampsia5. The 50 
strongest association is in pregnancies where preeclampsia developed in late gestation and 51 
offspring birthweights exceeded the 10th centile. An additional nearby variant, rs12050029, 52 
associates with preeclampsia independent of rs4769613. The newly discovered locus may enhance 53 
understanding of the pathophysiology of preeclampsia and its subtypes. 54 
 55 
Our initial GWAS meta-analysis tested 7,476,169 sequence variants in 2,658 offspring of 56 
preeclamptic pregnancies and 308,292 controls of European descent from Iceland (deCODE cohort) 57 
and the UK (GOPEC and ALSPAC cohorts). We observed a single genome-wide significant association  58 
(P=3.2×10-8, rs4769613) located on chromosome 13 near the FLT1 gene (Fig. 1a). We genotyped 59 
rs4769613 and a correlated surrogate in 1722 independent cases and 1946 controls from Norway 60 
and Finland along with 26 variants marking GWAS meta-analysis signals elsewhere in the genome 61 
whose P values showed suggestive evidence of association (Supplementary Table 1).  rs4769613 was 62 
significantly associated with preeclampsia in the replication datasets (P=3.6×10-4) and joint analysis 63 
of GWAS and replication data yielded robust genome-wide association (P=5.4×10-11) with an allelic 64 
odds ratio (OR) of 1.21 for allele C (Table 1).  Forest plots show the frequency of allele C is 65 
consistently elevated in cases in all GWAS and replication datasets with no evidence of 66 
heterogeneity (Phet=0.678; Supplementary Fig. 1). None of the other genotyped loci achieved 67 
genome-wide significance (P<5x10-8) in joint analysis of GWAS and replication data.    68 
 69 
We then examined genomic features of the FLT1 locus in detail (Fig. 1b) and found that some of the 70 
association signal remained after conditioning out the effect of rs4769613 (Fig 1b, bottom panel). 71 
This suggested that other variants near FLT1 might associate with preeclampsia independent of 72 
rs4769613. We therefore genotyped the replication datasets for 21 additional variants at the FLT1 73 
locus, representing 9 linkage disequilibrium (LD) blocks (Supplementary Table 2; Supplementary Fig. 74 
2). rs12050029 and surrogates in the same LD block were significant in combined analysis of GWAS 75 
and replication data after FLT1 region-wide correction for testing all common variants within 1 Mb of 76 
rs4769613 (P=3.9×10-6, Table 1). Table 1 shows that rs149427560 also achieved FLT1 region-wide 77 
significance but with an association signal weaker than rs12050029. In summary, our results imply 78 
that in addition to rs4769613, other independent variants near FLT1 may modulate preeclampsia 79 
susceptibility.  80 
As expected if risk allele rs4769613[C] increases susceptibility by acting through the fetal genome, 81 
Supplementary Table 3 shows that allele C frequency  in preeclampsia mothers  is midway between 82 
control frequency and the significantly elevated frequency in preeclampsia offspring. Preeclampsia 83 
offspring also preferentially inherited rs4769613[C] from heterozygous parents in the only dataset 84 
with DNA available for both parents, again implying that rs4769613[C] increases susceptibility by 85 
acting on the fetal genome (Supplementary Table 4). To examine if rs4769613 exerts effects on both 86 
the fetal and maternal genomes, we applied the EMIM algorithm which simultaneously evaluates 87 
maternal cases, offspring and controls to calculate ORs for preeclampsia risk corresponding to one or 88 
two risk alleles carried in the fetus (R1, R2) or in the mother (S1, S2) 6. Fig. 2a shows that fetal ORs are 89 
above 1.0 and that each fetal copy of rs4769613[C] increases these ORs. By contrast, maternal ORs 90 
are near 1.0 and are not significant. We conclude that rs4769613 exerts influence primarily through 91 
the fetal genome. 92 
 93 
As there is evidence that genetic imprinting may operate in placental development7 we examined 94 
rs4769613 allele transmissions from heterozygous parents, but found no parental gender difference 95 
in allele transmission in preeclampsia and hence no evidence for imprinting (χ2=0.046, P=0.83; 96 
Supplementary Table 5).   We also applied EMIM6  to meta-analyse cohorts with available DNA from 97 
one or both parents, but again found no evidence that maternal and paternal alleles at rs4769613 98 
confer differential preeclampsia risk (P=0.90). 99 
 100 
Sub-classifications of preeclampsia are based on clinical features, in particular gestation at diagnosis 101 
and evidence of fetal growth restriction (FGR)8. Early-onset preeclampsia (EO-preeclampsia), 102 
affecting 12-15% of all preeclamptic pregnancies and defined as onset before 34 weeks gestation, is 103 
associated with higher maternal and perinatal mortality than later onset preeclampsia (LO-104 
preeclampsia). It has been proposed that LO-preeclampsia results predominantly from maternal 105 
maladaptation to the physiological stresses of pregnancy, whilst EO-preeclampsia is primarily the 106 
result of sub-optimal placental implantation into the uterine wall, leading to inadequate placental 107 
perfusion and the release of damaging placental factors into the maternal circulation8.  In keeping 108 
with this, EO-preeclampsia is frequently associated with FGR, resulting in babies who are small for 109 
gestational age (SGA) at birth. SGA defined as birthweight <10th centile is widely used as a surrogate 110 
for FGR. 111 
To assess the impact of rs4769613 on gestation at onset and fetal growth subtypes we noted that 112 
rs4769613 risk allele C had higher frequency in LO-preeclampsia than EO-preeclampsia cases (case-113 
control OR 1.23 vs. 1.06) and found the difference was significant in case-case meta-analysis 114 
(P=0.017, Fig. 2b). Similarly, allele C had higher frequency in nonSGA-preeclampsia than SGA-115 
preeclampsia cases (case-control OR 1.25 vs 1.10) and the difference was significant in case-case 116 
comparison (P=0.019, Fig. 2b).  Further division of cases in Fig 2b into the four possible subcategories 117 
found that rs4769613 [C] confers greatest risk to LO+nonSGA cases (case-control OR=1.26, P=1.2×10-118 
7) and least risk to EO+SGA cases (case-control OR=1.03, P=0.72) with case-case comparison of the 119 
two subcategories being significant (P=5.8×10-3). In summary, the results indicate that rs4769613 120 
exerts its greatest influence in pregnancies where preeclampsia develops in late gestation and 121 
birthweights exceed the 10th centile. rs12050029 was also associated with LO-preeclampsia, but the 122 
strength of the association did not differ between SGA- and nonSGA-preeclampsia (Supplementary 123 
Fig. 3). 124 
 125 
FLT1 encodes a trans-membrane tyrosine kinase receptor Flt-1 that mediates angiogenesis 126 
promoted by binding vascular endothelial growth factor (VEGFA) and placental growth factor (PlGF)9. 127 
The alternatively spliced soluble isoform sFlt-1 antagonizes angiogenesis by also binding VEGFA and 128 
PlGF. During pregnancy, FLT1 is mainly expressed in fetal trophoblasts which release sFlt-1 as the 129 
most abundant isoform into the maternal circulation.   The excessive release of sFlt-1 in 130 
preeclampsia appears to mediate widespread maternal endothelial dysfunction, manifesting as 131 
hypertension, proteinuria, and vascular compromise to major organs. High sFlt-1 and low PlGF 132 
concentrations are established markers of EO-preeclampsia8, but our evidence that FLT1 133 
polymorphisms are strongly associated with LO-preeclampsia suggests trophoblast function is also 134 
important in this preeclampsia subgroup. 135 
 136 
The signals around rs4769613 and rs12050029 are both located in placental enhancer regions (Fig. 137 
1b) suggesting a mechanism by which variants could affect FLT1 expression. We explored possible 138 
association between fetal FLT1 genotype and protein expression by placental immunohistochemistry 139 
and intensity scanning in 37 preeclamptic and 44 control pregnancies. There was no detectable 140 
association between fetal rs4769613 genotype and trophoblast Flt-1 and sFlt-1 expression in cases 141 
(P=0.47) or controls (P=0.26). We also compared maternal serum sFlt-1 from the first or third 142 
trimester  with fetal rs4769613 genotype in mother-baby pairs from 242 control and 276 143 
preeclamptic pregnancies. Control pregnancies exhibited a trend towards increasing maternal serum 144 
sFlt-1 levels with each fetal copy of rs4769613[C] in the third trimester, which reached nominal 145 
significance (P = 0.04), while in case pregnancies the levels were higher (P<0.001) but with no 146 
detectable difference between genotype groups (P=0.47) (Fig. 2c). We did not have suitable 147 
placental tissue for mRNA studies, but the Genotype-Tissue expression (GTEx) database 148 
(www.gtexportal.org) does not provide evidence for rs4769613 or rs12050029 allele-specific 149 
differences in FLT1 expression in 42 tissues, although data for placental tissue are not recorded. The 150 
evidence that fetal rs4769613 genotype affects maternal serum levels of sFlt-1 is therefore modest. 151 
Subtle changes in sFlt-1 concentration driven by fetal FLT1 genotype, as suggested by the data from 152 
control pregnancies, may be masked in preeclampsia, where the overall levels are already high. Also, 153 
this effect is minimal compared to the increase in serum sFlt-1 seen in preeclamptic pregnancies so 154 
it may not reflect the role of the preeclampsia associated variants in the pathophysiology of 155 
preeclampsia.  156 
 157 
We explored whether the preeclampsia associated variants affected other diseases or traits by using 158 
the deCODE database of common diseases and traits routinely measured at hospitals and clinical 159 
laboratories (see Methods).  Given that rs4769613 and rs12050029 are not in LD (Supplementary Fig. 160 
2), it is noteworthy that the only significant database association for both variants was red blood cell 161 
(RBC) count (P=5.0 x 10-4 and P=1.5 x 10-7 for rs4769613 and rs12050029 respectively), where the 162 
preeclampsia risk allele  consistently associated with  reduced RBC count (Supplementary Table 6). 163 
The RBC association with FLT1 is intriguing since its VEGF ligand has previously been implicated in 164 
regulation of erythropoiesis, but the mode and sites of action are complex10,11. Our preeclampsia 165 
results suggest that in the fetus the two variants lead to an increase in sFlt-1, while the same alleles 166 
are associated with reduced RBC count in the general (non-pregnant) population. The effect on both 167 
preeclampsia and RBC is consistent with the variants acting through the neighbouring FLT1.  168 
We note that SNP rs4769613 is located between FLT1 and POMP, which encodes proteasome 169 
maturation protein, a ubiquitously expressed protein involved in proteasome assembly and MHC 170 
class I antigen presentation12. We cannot exclude the possibility that sequence variants at this locus 171 
affect expression of POMP or more distant genes, but the GTEx database does not provide any 172 
evidence to support this contention. 173 
 174 
Evidence presented here implies that altered trophoblastic FLT1 expression is not merely a 175 
secondary consequence of placental pathology in preeclampsia, but is central to its aetiology. A role 176 
for fetal sequence variants in susceptibility to preeclampsia is consistent with patterns of inheritance 177 
implicating both maternal and paternal factors2.  The fetal FLT1 gene has been indirectly implicated 178 
previously in pregnancies with fetal trisomy 13, which are associated with increased placental 179 
expression of sFlt-1, and an increased incidence of preeclampsia13. sFlt-1 is a marker of placental 180 
malfunction, a hallmark of EO-preeclampsia8; our observation that FLT1 genotype is associated even 181 
more strongly with LO-preeclampsia implies that placental pathology is also a feature of late-onset 182 
disease. The variants we describe provide tools for experimental testing of whether, how, when and 183 
where they affect FLT1 expression, and how this relates to the pathophysiology of preeclampsia and 184 
its subtypes. The discovery of sequence variants in the genome of the fetus that increase the risk of 185 
disease in the mother is an ultimate demonstration of the closeness of the remarkable symbiosis we 186 
call pregnancy. 187 
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Figure legends 297 
 298 
Figure 1 | Manhattan Plots showing GWAS results across all autosomes and detailed view near 299 
FLT1 on chromosome 13.  300 
a) Genome-wide Manhattan plot showing strength of association with PE in GWAS meta-analysis 301 
plotted as -log10(P value)  on the y-axis and corresponding variant position on the x-axis.   A single 302 
peak whose apex is the sentinel SNP rs4769613 near FLT1 on chromosome 13 crosses the blue line 303 
denoting genome-wide significance (P = 5×10-8).   Variants within 100 Kb of rs4769613 are coloured 304 
purple.   305 
b) Detailed view near FLT1 highlighting variants in Table 1.  Panels from top to bottom show: 306 
unconditional -log10(P value) from GWAS meta-analysis and  recombination rate shown as a blue 307 
line quantified by right hand y-axis; pattern of regional Linkage Disequilibrium (LD) shown by 308 
pairwise values of the LD metric D’; gene names with approximate length and position; the 309 
corresponding  chromatin state annotations for selected Epigenome Roadmap tissues 310 
(http://egg2.wustl.edu/roadmap/web_portal/chr_state_learning.html#core_15state); landscape of 311 
inferred chromatin interactions for 31 tissue types using an integrated method for predicting 312 
enhancer targets (IM-PET) (http://4dgenome.research.chop.edu/); conditional -log10(P value)  for 313 
GWAS meta-analysis using logistic regressions with rs4769613 as a covariate. 314 
  315 
Figure 2 | Key observations about rs4769613 in relation to preeclampsia.    316 
a) Forest plot showing Odds Ratio (OR) and 95% confidence intervals (95% CI) calculated by the 317 
EMIM algorithm6  for preeclampsia risk conferred by one or two copies of rs4769613 risk allele C 318 
carried in the fetus (R1, R2) or carried in the mother (S1, S2).  Individual datasets (GOPEC, MoBa, 319 
FINNPEC) and meta-analysis across the datasets ([Meta]) show the OR is increased by each fetal 320 
copy of risk allele C where for R1 P=3.7x10-4 and for R2 P=3.7x10-9.  By contrast, the OR for maternal 321 
copies (S1, S2) are not significantly different from 1 implying that, after accounting for fetal copies, 322 
maternal copies of allele C confer no additional increased risk of preeclampsia.    323 
b) Forest Plot for preeclampsia subtypes defined by early and late onset (EO-PE, LO-PE) and by 324 
birthweight that is small-for-gestational age (SGA-PE) or not (nonSGA-PE).  Case-case comparisons in 325 
blue font show risk allele C is more significantly associated with LO-PE and nonSGA-PE than with EO-326 
PE and SGA-PE. Dividing cases into the four possible subcategories found that allele C confers 327 
greatest risk to LO+nonSGA cases and least risk to EO+SGA cases.   328 
c) Box-and-whisker plots of first and third trimester maternal serum sFlt-1 concentration in 329 
preeclampsia cases and controls, showing the effect of fetal rs4769613 genotype. Boxes span the 330 
first to the third quartile of sFlt-1 concentration, with horizontal bars within the box denoting the 331 
median; whiskers extend to the 10th and 90th centiles. Maternal sFlt-1 is higher in cases than controls 332 
in the third trimester across all fetal genotypes (t-test ln(sFlt-1): t=7.79; 200 d.f.; 2-tailed P< 0.001). 333 
In third trimester controls, each copy of the rs4769613[C] allele carried by the fetus is associated 334 
with an increase in maternal sFlt-1 (linear regression of ln(sFlt) with SNP genotype (coded 0, 1 and 2) 335 
and gestational age as covariates: P=0.04). 336 
 337 
 338 
 339 
 340 
  341 
Table 1  Meta-analysis results at three independent variants near FLT1 giving evidence for association with 342 
preeclampsia 343 
 
    GWAS 
N=2,658 / 308,292 
Replication 
N=1,722 / 1,946 
 GWAS+Replication
N=4,380 / 310,238 
Variant 
Chr13 
Position 
Risk/Alt 
Allele RAF Covariate OR
 
95%CI P OR 95%CI 
 
P  OR 95%CI P 
rs4769613 29138609 C/T 0.53 None 1.22 1.14-1.31 3.2×10-8 1.18 1.08-1.30 3.6×10-4  1.21 1.14-1.28 5.4×10-11
rs12050029 29227519 G/A 0.14 None 1.20 1.09-1.33 1.5×10-4 1.18 1.05-1.32 5.9×10-3  1.19 1.11-1.28 3.0×10-6
rs149427560 29105870 G/GGT 0.06 None 1.30 1.14-1.49 9.3×10-5 1.16 0.96-1.40 1.1×10-1  1.23 1.09-1.38 4.1×10-5
rs12050029 29227519 G/A 0.14 rs4769613 1.19 1.09-1.32 2.9×10-4 1.18 1.05-1.33 4.2×10-3  1.19 1.11-1.28 3.9×10-6
rs149427560 29105870 G/GGT 0.06 rs4769613 1.31 1.15-1.50 6.7×10-5 1.17 0.97-1.41 9.1×10-2  1.23 1.10-1.38 2.4×10-5
 344 
Results are ordered by strength of association with preeclampsia in GWAS+Replication meta-analysis at three 345 
variants near FLT1 not in linkage disequilibrium. Row for rs4769613 is bold because its GWAS+Replication P value is 346 
genome-wide significant (p<5×10-8).  rs12050029 and rs149427560 are included in the table because their 347 
GWAS+Replication P values are below FLT1 region-wide significance threshold (6.01×10-5) calculated by the method 348 
of Gao (see Main Text and Methods).  “N”, total cases / controls in meta-analysis; “Chr13 Position”, NCBI Build 37 349 
position on chromosome 13; “Risk/Alt Allele”, allele with higher frequency in cases than controls and alternate allele; 350 
“RAF”, risk allele frequency in UK GWAS controls;  “Covariate”, covariate in conditional logistic regression;  “OR” and 351 
“95%CI”, allelic odds ratio and 95% confidence interval;  “P”,  P values of case-control association.  Genotypes of 352 
rs149427560 for the FINNPEC cohort were proxied from rs11619261 (pairwise r2=0.88 in Finland 1000Genomes 353 
phase 3). 354 
 355 
  356 
Methods 357 
Cohorts 358 
Three European cohorts of offspring from pregnancies affected by preeclampsia provided cases for 359 
GWAS meta-analysis: the GOPEC and ALSPAC cohorts from the UK, and the Icelandic deCODE cohort. 360 
Two independent cohorts were used for replication genotyping: the Finnish FINNPEC collection, and 361 
the Norwegian Mother and Child Cohort Study (MoBa).  Recruitment criteria were not identical in all 362 
cohorts, so subsets were selected for this study based on an internationally recognised definition of 363 
preeclampsia14: new-onset hypertension after the 20th week of gestation, with systolic blood 364 
pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on at least two occasions; and new-onset 365 
proteinuria of 0.3g/24 hours or more, or ≥1+ on dipstick analysis of urine. All were singleton 366 
pregnancies in a white Western European woman; preeclamptic pregnancies in women with a 367 
previous history of essential hypertension, type 1 or type 2 diabetes mellitus, ischaemic heart 368 
disease, cerebrovascular accident or chronic renal disease were excluded. Phenotypic details are 369 
summarised in Supplementary Tables 7 and 8. 370 
 371 
Written informed consent was obtained from participants, or from parents on behalf of minors, and 372 
all studies were approved by local Research Ethics Committees. 373 
GOPEC (Genetics of Pre-eclampsia) 374 
The UK GOPEC collection includes 1157 DNA samples from mother-baby pairs with preeclampsia 375 
recruited at diagnosis between 1992 and 2009 for genetic studies of preeclampsia15. Control data 376 
were derived from the WTCCC2 genome-wide analysis of 2930 samples from the 1958 Birth 377 
Cohort and 2737 samples from the National Blood Services, providing control data for 5297 378 
individuals after QC16.  379 
 380 
ALSPAC (Avon Longitudinal Study of Parents and Children) 381 
The ALSPAC prospective birth cohort study recruited pregnant women living in the South West of 382 
England between 1991 and 1992, and has been described elsewhere17. They included 13,678 383 
singleton pregnancies resulting in a live birth. After exclusion of women with existing hypertension, 384 
diabetes and gestational diabetes, there were 7382 pregnancies for which blood pressure and 385 
proteinuria measurements and fetal GWAS data were available. Of these, 146 met the definition of 386 
preeclampsia and were included. The control group of 6130 subjects was derived from all other 387 
included pregnancies with fetal GWAS data in women not affected by essential hypertension or 388 
gestational hypertension.  389 
  390 
deCODE Pre-eclampsia cohort 391 
The deCODE preeclampsia cohort is part of an ongoing sample collection including a large part of the 392 
Icelandic population. Preeclamptic pregnancies occurring between 1970 and 2009 were identified 393 
through scrutiny of hospital records at the Landspitali University Hospital, which provides secondary 394 
and tertiary services for the whole of Iceland. Initially, a group of women with hypertensive disease 395 
in pregnancy (ICD-9:642.0–9 and ICD-10: O10–16) in the years 1984-1999 were selected for further 396 
study based on familial relationships. All maternity records for these women were scrutinised and 397 
each affected pregnancy reclassified18. This identified 491 singleton preeclamptic pregnancies. 398 
Preeclamptic pregnancies from 2000-2009 were identified based on ICD-10 codes (O14-15), yielding 399 
1,311 additional singleton preeclamptic pregnancies. Overall information on 1,802 singleton 400 
preeclamptic pregnancies of 1,662 mothers is available.  GWAS data was available from 1507 401 
offspring of these pregnancies, identified retrospectively based on the national register. The control 402 
group comprises 296,865 individuals from the deCODE sample collection.  403 
  404 
MoBa (Norwegian Mother and Child Cohort Study) 405 
The Norwegian Mother and Child Cohort Study is a longitudinal study of over 110,000 pregnant 406 
women, their children and partners, recruited between 1999 and 2008 from maternity units 407 
throughout Norway19. 1200 pregnancies affected by preeclampsia were identified from Medical 408 
Birth Register of Norway records; the validity of the diagnosis has been assessed by retrieval and 409 
examination of antenatal records. 1200 non-hypertensive pregnancies provided the control group.  410 
Pregnancies were excluded from case and control groups if a maternal history of essential 411 
hypertension, chronic renal disease or diabetes mellitus was recorded in the Medical Birth Registry 412 
of Norway.  413 
   414 
FINNPEC (Finnish Genetic of Pre-eclampsia Consortium)  415 
The FINNPEC collection was assembled in Finland between 2008 and 2011 from two recruitment 416 
arms20. Samples were collected at the time of diagnosis of preeclampsia from 879 mothers, and 417 
during pregnancy from 922 non-pre-eclamptic mothers from antenatal and labour wards. Their 418 
children and partners were also enrolled. A further 525 pregnancies affected by preeclampsia were 419 
identified by examination of hospital records, and women and offspring were invited to participate 420 
by letter.  After exclusion of pregnancies which did not meet the entry criteria for this study, 421 
offspring of 605 preeclamptic pregnancies were included as cases, and offspring of 800 non-422 
hypertensive pregnancies provided the control group. 423 
 424 
Genotyping, quality control, genotype imputation and association analysis in GWAS datasets 425 
GOPEC  426 
1157 offspring of preeclamptic pregnancies were assayed on the Illumina OmniExpress chip; 427 
maternal samples where available were similarly genotyped.  A total of 730,525 variants were called 428 
with the GenCall algorithm. We carried out QC using PLINK 429 
(http://pngu.mgh.harvard.edu/~purcell/anal.shtml) and SMARTPCA21. A subset of the samples (186) 430 
were whole genome amplified (WGA). WGA genotype calls can be prone to calling artefacts.  To 431 
address this we removed variants with either low call rate (95%) or Mendelian errors in the WGA 432 
samples and we then performed a pseudo-case control analysis of WGA vs. non-WGA and removed 433 
variants with significant genotypic association (P<0.001). We then applied standard QC to the 434 
combined WGA and non-WGA dataset on this reduced set of variants (670,435).  Briefly, standard 435 
QC comprises the following subject level exclusion criteria: individual call-rate < 95%; heterozygosity 436 
>3 s.d. from the mean; any of the first 3 HapMap (based on CEU, YRI, CHB, JPT and GIH) principal 437 
axes of variation >4 s.d. from the mean and gender mismatch.  Related individuals (IBD>0.1) with 438 
lowest call-rate were preferentially removed. The variant level exclusion criteria are: call-rate <95%, 439 
exact Hardy-Weinberg equilibrium P<1 x 10-6, minor allele frequency (MAF) <1% and non-random 440 
missingness of uncalled genotypes ("plink --test-mishap”) with Bonferroni corrected P<0.05.  These 441 
filters left 1005 samples (89 WGA) and 574,919 variants.  442 
 443 
We used WTCCC2 population controls from the National Blood Donors Cohort and UK 1958 Birth 444 
Cohort16. These samples were genotyped on the Illumina 1.2M chip and called using GenCall.   445 
Strand ambiguous markers were removed and the standard QC described above was then applied to 446 
the two control datasets. The merged control datasets consisted of 5,297 samples and 438,912 447 
variants. This control dataset was merged with the case dataset resulting in 429,754 post QC variants 448 
that were genotyped in both cases and controls. 449 
 450 
Cases and controls were imputed together with IMPUTE2 (impute_v2.3.0)22 and SHAPEIT23 using the 451 
pre-phasing workflow against the 1000 Genomes Phase 1 reference panel (Dec. 2013) downloaded 452 
from the IMPUTE2 website. Imputation resulted in 10,404,388 bi-allelic variants with MAF > 0.25% 453 
that were either directly genotyped or imputed with IMPUTE2 INFO score >0.6.  454 
 455 
Post imputation association analysis was carried out using SNPTEST (v2.4.1)22 with the "expected" 456 
method with no ancestry principal components.  We calculated the genomic control on variants with 457 
MAF>0.5% as λGC =1.005. 458 
 459 
deCODE  460 
Details of GWAS genotyping, QC and imputation of the Icelandic dataset including the preeclampsia 461 
cases and controls used in this study have been described24. Briefly, samples were assayed with the 462 
Illumina HumanHap300, HumanCNV370, HumanHap610, HumanHap1M, HumanHap660, Omni-1, 463 
Omni 2.5 or Omni Express bead chips at deCODE genetics. Following QC a final set of 676,913 464 
autosomal SNPs were used for long range phasing of all chip-genotyped samples. Making use of the 465 
Icelandic genealogy untyped first and second degree relatives of chip-typed individuals were also 466 
included in the analysis to increase power24. In total 104,220 chip-typed individuals and 294,212 of 467 
their untyped relatives were imputed based on a panel of sequence variants identified through 468 
whole genome sequencing of 2,636 Icelanders to a mean depth of 20x. 469 
 470 
GWAS analysis of Icelandic preeclampsia offspring included a total of 1,507 cases (380 chip typed) 471 
and 296,865 controls (91,326 chip-typed). The controls used in this study were Icelandic individuals 472 
from other ongoing GWAS studies at deCODE and their relatives. Logistic regression was used to test 473 
for association between sequence variants and disease, treating disease status as the response and 474 
genotype counts as covariates. Other characteristics also included in the model as nuisance variables 475 
were: sex, county of birth, current age or age at death (first and second order terms included), 476 
genotyping status and an indicator function for the overlap of the lifetime of the individual with the 477 
timespan of phenotype collection25. In order to account for relatedness and stratification within the 478 
case and control sample sets we applied the method of genomic control25. Based on a set of about 479 
300,000 common variants distributed across the genome the inflation in the chi-squared statistic for 480 
preeclampsia offspring was estimated to be 1.115. 481 
 482 
ALSPAC 483 
A total of 9,912 ALSPAC children were genotyped using the Illumina HumanHap550 quad genome-484 
wide SNP genotyping platform (Illumina Inc., San Diego, CA, USA) by Logistics and Genotyping 485 
Facilities at the Wellcome Trust Sanger Institute and Laboratory Corporation of America (LabCorp 486 
Holdings., Burlington, NC, USA). PLINK software (v1.07) was used to carry out quality control 487 
measures. Individuals were excluded from further analysis on the basis of having incorrect gender 488 
assignments, minimal or excessive heterozygosity (< 0.320 and > 0.345 for the Sanger data and < 489 
0.310 and > 0.330 for the LabCorp data), disproportionate levels of individual missingness (> 3%) and 490 
being of non-European ancestry (as detected by a multidimensional scaling analysis seeded with 491 
HapMap 2 individuals). EIGENSTRAT analysis revealed no additional obvious population stratification 492 
and genome-wide analyses with other phenotypes in the same cohort indicate a low lambda. SNPs 493 
with a minor allele frequency of < 1% and call rate of < 95% were removed. Furthermore, only SNPs 494 
that passed an exact test of Hardy–Weinberg equilibrium (P > 5×10-7) were considered for analysis. 495 
Related subjects (> 10% IBD) that passed all other quality control thresholds were retained during 496 
subsequent phasing and imputation. 9,115 subjects and 500,527 SNPs passed these quality control 497 
filters.  498 
We combined 477,482 SNP genotypes in common between the sample of children and mothers. 499 
Genotyping and QC of the ALSPAC mothers can be found elsewhere26. SNPs with genotype 500 
missingness > 1% and those that failed the exact test of HWE were removed. A further 321 501 
participants were removed due to potential ID mismatches (IBD < 1). The resultant dataset 502 
comprised 17,842 subjects of which 6,305 were mother-offspring pairs. An additional 112 SNPs were 503 
removed after a liftover of the merged genotyped data from Hg 18 to Hg19. Haplotype phasing was 504 
performed using SHAPEIT (v2.r644)23 and known autosomal variants were imputed with IMPUTE 505 
V2.2.222 using the 1000 genomes reference panel (Phase 1, Version 3) consisting of 2186 reference 506 
haplotypes (including non-Europeans).  507 
 508 
Logistic regression, as implemented in SNPTEST v2.5-beta422, was used to test for association 509 
between imputed genotype probabilities and disease status. Based on a set of ~9 million SNPs 510 
(MAF>0.5% and IMPUTE2 INFO>0.6), no evidence of genomic inflation was observed (λGC =1.008).  511 
 512 
Follow-up genotyping  513 
Follow-up variants in the FLT1 locus were chosen to test association with the rs4769613 peak and to 514 
test possible association in the other 8 FLT1 LD blocks shown in Supplementary Fig. 2.  Some 515 
genotyped variants were highly correlated surrogates of rs4769613 or of other follow-up SNPs in 516 
case the assay for the primary variant failed, and to ensure that assertion of a true-positive 517 
association did not rely on genotyping of a single variant.  Follow-up variants in non-FLT1 regions of 518 
the genome were chosen based on GWAS meta-analysis P value and were selected to further test 519 
suggestive evidence of association exhibited by the top GWAS discovery meta-analysis signals.  520 
Replication genotyping was performed at the Wellcome Trust Sanger Institute using Sequenom iPLEX 521 
assays, and at the British Heart Foundation Glasgow Cardiovascular Research Centre using TaqMan 522 
Open Array genotyping. Variants were excluded from analysis if they had call rates < 95%; subjects 523 
with call rates < 80%, and families in the MoBa cohort that exhibited more than 1 Mendelian error 524 
were also excluded. For four variants (rs7305125, rs149427560, rs12050029 and rs4769628) follow-525 
up data for the MoBa samples was in silico data based on 1046 cases and 961 controls assayed on 526 
the Illumina HumanCoreExome-12 v1.1 chip and imputed based on the 1000 Genomes Phase 3 527 
reference panel. Of those, 908 cases and 909 controls were also included in the directly genotyped 528 
MoBa replication set. 529 
 530 
Meta-analysis   531 
Prior to meta-analysis GWAS results were adjusted by a genomic control λGC factor where 532 
appropriate as described above for each GWAS cohort. Study level variants with a MAF<0.5% or an 533 
imputation quality score <0.6 were excluded from the analysis. This left 7,476,169 autosomal 534 
variants for analysis. The GWAS and the GWAS+Replication meta-analyses were conducted using the 535 
fixed effect inverse variance weighting method implemented in MetaSoft27. No genomic control 536 
adjustment was applied to the GWAS meta-analysis results since the inflation factor was negligible 537 
(λGC =1.0075).  538 
Conditional and FLT1 region-wide analyses 539 
The association between disease status on a variant conditional on rs4769613 was assessed by 540 
inverse variance weighted meta-analysis of the per cohort conditional analyses. Individual cohorts 541 
were analysed by logistic regression of the disease status against expected genotype dose with the 542 
expected doses of conditioning variants included as covariates. This approach was implemented for 543 
each cohort as follows: MoBa and FINNPEC replication cohorts were analysed using “plink --544 
condition”; GOPEC and MoBa GWAS were analysed using “snptest  -condition_on”; the deCODE 545 
association analysis is described above; ALSPAC conditional associations were inferred from the 546 
summary association statistics with the use of the 1000 Genomes Phase 3 EUR samples  to estimate 547 
the LD structure using the joint analysis method28.  We assessed the region-wide effective number of 548 
tests using the method of Gao29 on the imputed WTCCC2 UK control dataset for the 5405 common 549 
variants (MAF>5%) within 1Mb of rs4769613, yielding a total of 832 independent tests and hence a 550 
FLT1 region-wide significance threshold of 0.05/832=6.01×10-5. 551 
Maternal, fetal and parent-of-origin effect analysis 552 
The family genotype data was jointly analysed using the EMIM method6.The subjects were first 553 
partitioned into maximal family groups within each cohort (Supplementary Table 9). We then fitted 554 
EMIM models assuming Hardy-Weinberg equilibrium and Exchangeable Parental Genotypes. We 555 
considered two parameter sets: maternal and fetal effects (R1, R2, S1 and S2) and maternal, fetal and 556 
parent of origin effect (R1, R2, S1, S2 and Im) where Im is the odds-ratio associated with the maternal 557 
transmission of the risk allele. The per cohort results were combined using inverse variance 558 
weighted meta-analysis. 559 
Preeclampsia subtype analysis 560 
To analyse the relation between rs4769613 and preeclampsia subtypes we pooled genotype and 561 
clinical data of the GOPEC, FINNPEC and MoBa cohorts (Supplementary Table 8). The phenotype 562 
associations were calculated using logistic regression with cohort and FINNPEC recruitment region 563 
included as indicator variables.  564 
deCODE phenotype database 565 
The deCODE Genetics phenotype database contains medical information on diseases and traits 566 
obtained through collaboration with specialists in each field. This includes information on 567 
cardiovascular diseases (myocardial infarction, coronary arterial disease, peripheral arterial disease, 568 
atrial fibrillation, sick sinus syndrome and stroke), metabolic disorders (obesity, diabetes, and 569 
metabolic syndrome), psychiatric disorders (schizophrenia, bipolar disorder, anxiety and depression), 570 
addictions (nicotine, alcohol), inflammatory diseases (rheumatoid arthritis, lupus, and asthma), 571 
musculoskeletal disorders (osteoarthritis, osteoporosis), eye diseases (glaucoma), kidney diseases 572 
(kidney stones, kidney failure) and 29 types of cancer. Anthropometric measures have also been 573 
collected through several of these projects. Routinely measured traits from patient workups 574 
(sodium, potassium, bicarbonate, calcium, phosphate, creatinine, blood cell counts, haemoglobin, 575 
haematocrit, 15 immunoglobulins, iron, vitamins, lipids, liver function tests and more) were obtained 576 
from the Landspitali University Hospital, Reykjavík, and the Icelandic Medical Center Laboratory in 577 
Mjodd (Laeknasetrid), Reykjavik. The number of independent and uncorrelated secondary traits 578 
tested for association amounts to 400. 579 
 580 
Placental expression of Flt1 and sFlt1 581 
Women with singleton pregnancies delivering by caesarean section were recruited to the Pre-582 
eclampsia Study between 2002 and 2012 at St. Olavs Hospital, Trondheim University Hospital and 583 
Haukeland University Hospital, Bergen. Healthy and pre-eclamptic pregnancies were included as 584 
described previously30. A tangential section (100 mg) from the maternal central side of the placenta 585 
was collected directly after delivery, fixed in 10% neutral-buffered formalin and paraffin embedded. 586 
Tissue sections of 3 μm were pre-treated in Target Retrieval Solution (#K8004, Dako) and stained by 587 
Flt-1 antibody (1:175, # ab32152, Abcam) using EnVision (#K4011, Dako) according to the 588 
manufacturer’s protocol. This Flt-1 antibody recognises membrane-bound Flt-1 and splice isoforms 589 
sFlt-1, sFlt1-14, and isoform 4 (61 kDa). Staining was performed using Autostainer Plus (#S3800, 590 
Dako) and images taken at two sites per placenta with an Eclipse E400 microscope and DS-Fi1 591 
camera. Staining intensity in syncytiotrophoblast was analysed by NIS-Elements BR 4.0 software 592 
(Nikon), excluding immature villi, and blinded for pregnancy outcomes. Staining intensity data were 593 
analysed separately in a general linear model incorporating SNP genotype, gestational age and 594 
hospital of origin as cofactors.  595 
 596 
Maternal serum sFlt1 and fetal genotype 597 
We identified mother-baby pairs from the FINNPEC collection for whom offspring DNA and maternal 598 
serum samples from the first and/or third trimester of pregnancy were available for analysis. 599 
Maternal serum sFlt-1 concentration was measured using electrochemiluminescence immunoassays 600 
(ECLIA; Roche Diagnostics GmbH, Mannheim, Germany) on a Cobas e 601 analyzer (Hitachi High 601 
Technology Co, Tokyo, Japan). Offspring genotype at rs4769613 was determined by Sequenom 602 
MassArray iPLEX genotyping in the FiMM Technology Centre (University of Helsinki, Finland). 603 
Investigators were blinded for pregnancy outcome during sample analysis. Serum sFlt-1 data were 604 
normalized by logarithmic transformation. Case and control data were compared by unpaired t-605 
testing; genotypic associations with serum sFlt-1 were examined separately in cases and controls in a 606 
linear model, with SNP genotype and gestational age as covariates.  607 
 608 
Data Availability  609 
Meta-analysed GWAS data used in this study, and individual-level GWAS data from the 610 
GOPEC cohort, are deposited in the European Genome-phenome Archive 611 
(www.ebi.ac.uk/ega) with accession numbers EGAD00010001211 and EGAD00010001212. 612 
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 Supplementary Table 1  Meta-analysis of variants selected for post-GWAS follow-up 
 
      GWAS 
N=2,658 / 308,292 
 Replication
 
N=1,722 / 1,946
 
 GWAS+Replication
 
N=4,380 / 310,238
 
Variant 
Nearest 
Gene Chr 
 
Position 
Risk/Alt 
Allele RAF  OR 
 
95%CI P  OR 95%CI 
 
P  OR 95%CI P 
rs16835173 PCGEM1 2 194213678 T/C 0.02 
 
1.61 1.33-1.96 1.8×10
-6
 
 
1.26 0.88-1.82 0.20 
 
1.53 1.28-1.81 1.5×10
-6
 
rs78689834 PARD3B 2 205388423 A/C 0.02 
 
1.58 1.31-1.92 3.0×10
-6
  0.88 0.65-1.19 0.40  1.34 1.14-1.57 4.9×10
-4
 
rs73843515 CADM2 3 85984083 T/C 0.01 
 
2.01 1.48-2.74 8.8×10
-6
  0.78 0.40-1.49 0.45  1.69 1.28-2.23 2.2×10
-4
 
rs9846396 ZBTB38 3 141140968 C/T 0.56 
 
1.14 1.06-1.22 3.6×10
-4
  1.00 0.86-1.17 0.98  1.10 1.04-1.17 2.1×10
-3
 
rs112342656 MCC 5 112656059 C/T 0.01 
 
1.90 1.45-2.48 2.7×10
-6
  0.71 0.46-1.10 0.12  1.45 1.15-1.82 1.5×10
-3
 
rs11740989 JAKMIP2 5 147160125 C/T 0.05 
 
1.37 1.20-1.58 7.1×10
-6
  1.05 0.84-1.32 0.67  1.28 1.14-1.44 5.0×10
-5
 
rs16898533 SLC25A51P1 6 67269926 G/T 0.04 
 
1.46 1.25-1.71 3.0×10
-6
  0.87 0.64-1.17 0.35  1.30 1.13-1.50 2.3×10
-4
 
rs9397792 TIAM2 6 155543913 G/T 0.14 
 
1.26 1.14-1.38 2.5×10
-6
  1.06 0.90-1.25 0.47  1.20 1.11-1.31 9.2×10
-6
 
rs12154986 FAM220A 7 6398651 A/G 0.72 
 
1.15 1.06-1.25 5.4×10
-4
  1.11 1.01-1.23 0.04  1.14 1.07-1.21 5.8×10
-5
 
rs6577900 FAM135B 8 139255733 C/T 0.32 
 
1.15 1.07-1.24 2.1×10
-4
  1.02 0.90-1.16 0.70  1.12 1.05-1.19 7.4×10
-4
 
rs2427981 SARDH 9 136581419 A/C 0.58 
 
1.18 1.09-1.27 1.1×10
-5
  0.95 0.85-1.08 0.45  1.14 1.07-1.21 3.5×10
-5
 
rs3750804 TCF7L2 10 114833850 C/T 0.62 
 
1.19 1.10-1.29 2.9×10
-5
  1.08 0.95-1.24 0.22  1.16 1.08-1.24 2.6×10
-5
 
rs11197042 ATRNL1 10 116825666 A/G 0.29 
 
1.18 1.09-1.27 2.7×10
-5
  0.93 0.82-1.05 0.26  1.10 1.03-1.18 2.8×10
-3
 
rs1586382 ZBED5-AS1 11 11074260 T/G 0.73 
 
1.15 1.06-1.24 1.0×10
-5
  1.02 0.90-1.17 0.72  1.10 1.02-1.17 9.4×10
-3
 
rs11227306 OVOL1 11 65578672 A/C 0.38 
 
1.16 1.08-1.25 4.4×10
-5
  1.06 0.96-1.17 0.28  1.12 1.06-1.19 7.7×10
-5
 
rs501630 EFEMP2 11 65637273 A/G 0.45 
 
1.15 1.07-1.23 1.1×10
-4
  1.04 0.92-1.16 0.54  1.12 1.05-1.19 3.0×10
-4
 
rs7305125 ITPR2 12 26960599 C/G 0.31 
 
1.19 1.10-1.29 6.8×10
-6
  1.06 0.92-1.22 0.88  1.16 1.09-1.24 1.3×10
-5
 
rs118009336 DNAH10 12 124410135 A/C 0.96 
 
1.56 1.28-1.90 8.6×10
-6
  0.98 0.75-1.26 0.85  1.31 1.12-1.53 6.4×10
-4
 
rs4769613 FLT1 13 29138609 C/T 0.53 
 
1.22 1.14-1.31 3.2×10
-8
  1.18 1.08-1.30 3.6×10
-4
  1.21 1.14-1.28 5.4×10
-11
 
rs7328374 FLT1 13 29141327 T/C 0.52 
 1.21 1.13-1.30 9.6 10
-8
  1.19 1.09-1.31 2.1×10
-4
  1.20 1.14-1.27 8.6×10
-11
 
rs11623923 SLC35F4 14 58042753 G/A 0.84 
 
1.18 1.07-1.31 1.1×10
-3
  1.04 0.88-1.22 0.65  1.14 1.05-1.24 2.7×10
-3
 
rs72747221 GCOM1 15 58058582 C/T 0.96 
 
1.74 1.36-2.24 1.1×10
-5
  0.89 0.65-1.21 0.45  1.33 1.10-1.62 3.4×10
-3
 
rs12962662 TNFRSF11A 18 60104589 T/C 0.16 
 
1.25 1.14-1.38 3.7×10
-6
  1.03 0.87-1.22 0.72  1.19 1.10-1.29 2.7×10
-5
 
rs6566644 CBLN2 18 70310180 G/T 0.54 
 
1.18 1.10-1.27 3.0×10
-6
  1.10 0.98-1.23 0.12  1.16 1.09-1.23 1.5×10
-6
 
rs56090944 MMP24 20 33813993 A/G 0.04 
 
1.44 1.24-1.66 1.4×10
-6
  1.06 0.82-1.38 0.64  1.34 1.18-1.52 9.2×10
-6
 
rs2071969 L3MBTL1 20 42160962 G/A 0.90 
 
1.25 1.11-1.41 2.4×10
-4
  0.88 0.73-1.05 0.16  1.12 1.02-1.24 2.1×10
-2
 
rs1412977 C20orf85 20 56709290 G/T 0.51 
 
1.18 1.09-1.26 9.5×10
-6
  1.08 0.99-1.19 0.09  1.14 1.08-1.21 5.6×10
-6
 
rs73306896 ZNF831 20 57750533 T/C 0.12 
 
1.21 1.09-1.34 2.3×10
-4
  1.11 0.94-1.31 0.21  1.18 1.08-1.29 1.5×10
-4
 
 
Variants in the table are ordered by chromosome number (“Chr”) and NCBI Build 37 position (“Position”).  “N”, total cases / controls in meta-
analysis;  “Risk/Alt Allele”, allele with higher frequency in GWAS cases than controls and alternate allele; “RAF”, risk allele frequency in UK 
GWAS controls;  “OR” and “95% CI”,  allelic odds ratio and 95% confidence interval.  “P”, P values of case-control association. Rows for 
rs4769613 and its near-perfect surrogate rs7328374 are bold because their GWAS+Replication P values are below genome-wide 
significance of 5×10
-8
   No other follow-up variants achieved genome-wide significance. 
 
 
 
  
 Supplementary Table 2   Meta-analysis results at all variants near FLT1 followed up in the replication datasets 
 
    GWAS 
N=2,658 / 308,292 
 Replication
 
N=1,722 / 1,946
 
 GWAS+Replication
 
N=4,380 / 310,238
 
Variant 
Chr13 
Position 
Risk/Alt 
Allele RAF  OR 
 
95%CI P  OR 95%CI 
 
P  OR 95%CI P 
rs3794401 28915659 A/G 0.87  1.20 1.07-1.35 1.6×10
-3
  1.09 0.95-1.26 0.22  1.16 1.06-1.26 1.3×10
-3
 
rs2296284 28963676 A/G 0.29  1.01 0.94-1.09 7.9×10
-1
  0.99 0.87-1.12 0.83  1.00 0.94-1.07 9.1×10
-1
 
rs9319429 28973703 T/C 0.30  1.01 0.94-1.09 8.0×10
-1
  1.00 0.88-1.13 0.97  1.01 0.94-1.07 8.4×10
-1
 
rs11619261 29078077 A/G 0.07  1.25 1.10-1.42 6.4×10
-4
  1.18 0.99-1.39 0.06  1.22 1.10-1.35 1.1×10
-4
 
rs149427560 29105870 G/GGT 0.06  1.30 1.14-1.49 9.3×10
-5
  1.16 0.96-1.40 0.11  1.23 1.09-1.38 4.1×10
-5
 
rs4769613 29138609 C/T 0.53  1.22 1.14-1.31 3.2×10
-8
  1.18 1.08-1.30 3.6×10
-4
  1.21 1.14-1.28 5.4×10
-11
 
rs7328374 29141327 T/C 0.52  1.21 1.13-1.30 9.6×10
-8
  1.19 1.09-1.31 2.1×10
-4
  1.20 1.14-1.27 8.6×10
-11
 
rs17555115 29143824 G/A 0.52  1.21 1.13-1.30 1.6×10
-7
  1.12 0.99-1.27 0.07  1.19 1.12-1.26 5.1×10
-8
 
rs3829387 29149693 C/A 0.21  1.22 1.12-1.32 3.1×10
-6
  1.09 0.95-1.26 0.22  1.19 1.10-1.27 3.3×10
-6
 
rs9508065 29151651 A/C 0.22  1.19 1.09-1.30 9.4×10
-5
  1.08 0.97-1.21 0.16  1.15 1.07-1.23 8.1×10
-5
 
rs9508079 29169711 G/A 0.54  1.06 0.99-1.14 1.1×10
-1
  1.05 0.92-1.20 0.45  1.06 0.99-1.12 8.0×10
-2
 
rs117488563 29183168 A/G 0.06  1.32 1.14-1.53 2.1×10
-4
  1.20 0.86-1.67 0.28  1.30 1.14-1.48 1.3×10
-4
 
rs2096035 29184460 A/G 0.81  1.17 1.06-1.28 1.3×10
-3
  1.05 0.90-1.22 0.56  1.13 1.04-1.23 2.4×10
-3
 
rs4769620 29184950 C/T 0.81  1.16 1.06-1.28 1.5×10
-3
  1.03 0.91-1.17 0.64  1.11 1.03-1.20 4.7×10
-3
 
rs9508092 29186162 T/C 0.80  1.16 1.06-1.27 1.7×10
-3
  1.07 0.94-1.21 0.34  1.13 1.05-1.22 1.8×10
-3
 
rs35242283 29211289 A/AGAT 0.14  1.22 1.11-1.34 6.4×10
-5
  1.25 1.07-1.47 6.4×10
-3
  1.23 1.13-1.33 1.4×10
-6
 
rs71433277 29218967 T/C 0.14  1.22 1.10-1.34 7.9×10
-5
  1.14 1.02-1.29 0.03  1.19 1.10-1.28 7.6×10
-6
 
rs1185049 29226634 G/A 0.34  1.17 1.09-1.26 1.7×10
-5
  1.09 0.99-1.20 0.06  1.14 1.08-1.21 5.6×10
-6
 
rs12050029 29227519 G/A 0.14  1.20 1.09-1.33 1.5×10
-4
  1.18 1.05-1.32 5.9×10
-3
  1.19 1.11-1.28 3.0×10
-6
 
rs9551517 29230045 A/G 0.34  1.18 1.09-1.26 1.1×10
-5
  1.09 1.00-1.20 0.06  1.15 1.08-1.21 3.5×10
-6
 
rs4769628 29232064 G/A 0.15  1.21 1.10-1.33 1.3×10
-4
  1.17 1.04-1.32 7.1×10
-3
  1.19 1.11-1.28 3.0×10
-6
 
 
All results are from unconditional logistic regression and are listed by NCBI Build 37 variant position on chromosome 13 (“Chr13 
Position”).  “N”, total cases / controls in meta-analysis;  “Risk/Alt Allele”, allele with higher frequency in GWAS cases than controls and 
alternate allele; “RAF”, risk allele frequency in UK GWAS controls;  “OR” and “95% CI”, allelic odds ratio and 95% confidence interval.  
Rows for rs4769613 and its near-perfect surrogate rs7328374 are in bold to highlight genome-wide significance (P<5×10
-8
) of their 
GWAS+Replication P values. Genotypes of rs149427560 for the FINNPEC replication cohort were proxied from rs11619261 (pairwise 
r
2
=0.88 in Finland 1000Genomes phase 3); results for several variants do not include FINNPEC data (rs17555115, rs3829387, 
rs2096035, rs2296284 and rs9319429) because they were not genotyped in FINNPEC.  Most of these variants were not genotyped since 
they are in strong LD and redundant with other variants genotyped in FINNPEC. 
 
  
 Supplementary Table 3 | Frequency of rs4769613 risk allele C in preeclampsia offspring cases, maternal cases, and controls 
 
 Offspring Cases 
 
Maternal Cases 
 
Controls 
Cohort Freq se OR P 
 
Freq se OR P 
 
Freq se 
GOPEC 0.576 0.011 1.231 2.74×10
-5
 
 
0.555 0.008 1.131 0.0014 
 
0.524 0.005 
deCODE 0.567 0.017 1.229 5.49×10
-4
 
 
0.557 0.010 1.095 0.0242 
 
0.531 0.001 
MoBa 0.544 0.011 1.100 7.71×10
-2
 
 
0.519 0.010 0.996 0.9610 
 
0.520 0.008 
FINNPEC 0.538 0.015 1.334 2.69×10
-4
 
 
0.489 0.013 1.096 0.2080 
 
0.466 0.012 
 
Cohort sample numbers (Offspring cases/Maternal cases/Controls) are:  GOPEC(1004/1875/5083), deCODE(411/1205/135190), MoBa(1125/1169/1927), 
FINNPEC(527/729/870);  “Freq” and “se” are mean allele frequency and standard error for risk allele C; “OR” and “P” are allelic odds ratio and case-control P 
value calculated by Pearson 
2
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Table 4 | Transmission Disequilibrium Test of rs4769613 alleles transmitted  
from heterozygous (C/T) parents to offspring in preeclampsia and control trios of the MoBa cohort  
 
 
Allele Transmissions 
Test for preferential 
inheritance of allele C 
Phenotype C T %C TDT 
2
 P 
Preeclampsia 
case trios 
417 361 53.6% 4.031 0.045 
Control trios 351 341 50.7% 0.145 0.704 
 
All MoBa trios with genotyped DNA from both parents and child are included. 
“C” and “T” show total counts of risk allele C and alternate allele T transmitted from each heterozygous 
(C/T) parent to an offspring.  “%C” is percentage of risk allele C among total transmitted alleles and 
shows preferential inheritance of allele C (53.6%) by preeclampsia offspring but nearly equal inheritance 
(50.7%) by offspring in control families; TDT 
2
=(C-T)
2
/(C+T)  derived in Spielman et al (American 
Journal of Human Genetics 52:506-516, 1993) shows statistical significance (p<0.045) of preferential 
allele C inheritance by preeclampsia cases but non-significance (p=0.704) in control trios. 
  
Supplementary Table 5 | Test for sex difference between heterozygous (C/T) mothers 
and fathers in transmission of rs4769613 alleles to preeclampsia offspring of MoBa cohort 
 
 
Allele Transmissions Test Sex Difference 
Parental Sex C T %C χ
2
 P 
Mother 164 134 55.0% 
0.0462 0.83 
Father 169 143 54.2% 
 
“C” and “T” show total counts of risk allele C and alternate allele T transmitted from each heterozygous 
(C/T) parent to an offspring.  “%C” is percentage of allele C among total transmitted alleles. 
Preeclampsia trios are included only if maternal and paternal allele transmissions are unambiguous (i.e. 
preeclampsia trios were excluded if both parents and offspring were heterozygous).  “
2
” is 2x2 Pearson 
χ
2
 Test on counts of allele C and T transmitted from heterozygous mothers versus fathers in 
unambiguous preeclampsia trios. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Supplementary Table 6 | Association results for Red Blood Cell (RBC) count, haemoglobin and 
haematocrit for preeclampsia associated variants 
 
SNP 
Risk 
allele* 
Other 
allele 
Risk 
allele 
frequency Trait
†
 N samples
‡
 P value Effect
§
 95%CI 
rs4769613 C T 0.53 RBC count 270,314 5.0 x 10
-4
 -0.011 -0.005 to -0.017 
    
Haemoglobin 272,616 7.1 x 10
-4
 -0.010 -0.004 to -0.016 
    
Haematocrit 268,150 2.5 x 10
-3
 -0.009 -0.003 to -0.015 
rs12050029 G A 0.14 RBC count 270,314 1.5 x 10
-7
 -0.024 -0.033 to -0.015 
    
Haemoglobin 272,616 1.1 x 10
-4
 -0.016 -0.024 to -0.008 
    
Haematocrit 268,150 4.0 x 10
-6
 -0.019 -0.027 to -0.011 
* Allele associated with increased risk of preeclampsia 
† 
Results are shown for three correlated traits 
‡
 Number of individuals included in the analysis 
§
 Effect estimate in units of standard deviation is reported for the designated Risk allele. Association was tested using generalized 
linear regression. Measurements were adjusted for age, sex and measurement site, and average was taken over the available 
measurements after adjustment and inverse normal transformation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Table 7 | Characteristics of pregnancies from GWAS and Replication cohorts 
 
Cohort and  
country of origin Group Maternal age 
Primi- 
parous 
Highest SBP 
(mm Hg) 
Highest DBP 
(mm Hg) 
Gestation at delivery 
(weeks) 
Offspring 
birthweight (grams) 
  Mean SD  Mean SD Mean SD Median IQR Median IQR 
             
GOPEC
◊
 
UK 
Cases 
n=1157 
29.6 5.6 78% 167 18 111 9 37 34-38 2580 1848-3193 
             
ALSPAC 
UK 
Cases 
n=146 
28.7 5.3 68% 159 13 108 9 39 37-40 3240 2710-3680 
             
ALSPAC 
UK 
Controls 
n=6130 
28.6 4.8 41% 127 10 78 7 40 39-41 3460 3160-3780 
             
deCODE
□
  
Iceland 
Cases 
n=1507 
27.8 6.0 66% 155
‡ 
16 107
‡ 
9 39 37-40 3310
§ 
2752-3744 
             
MoBa 
Norway 
Cases 
n=1200 
29.1  4.8 66% Not  
available 
 Not  
available 
 39 38-41 3325 2812-3740 
             
MoBa 
Norway 
Controls 
n=1200 
30.1 4.4 42% Not  
available 
 Not  
available 
 40 39-41 3690 3341-4010 
             
FINNPEC  
Finland 
Cases 
n=605 
29.9 5.6 75% 166 17 109 9 38 36-39 2913 2390-3380 
             
FINNPEC  
Finland 
Controls 
n=800 
29.7 
 
5.1 56% 128 14 85 10 40 39-41 3590 3260-3930 
 
Phenotypic data were available for >99% of pregnancies unless otherwise indicated.  
SBP, systolic blood pressure; DBP, diastolic blood pressure; IQR, interquartile range 
‡
 491 pregnancies 
§ 
1294 pregnancies 
◊ 
Control data for GOPEC GWAS were derived from 5297 unselected subjects from the UK population included in the 1958 Birth Cohort and donors to the 
National Blood Service 
□
 Control data for deCODE GWAS were derived from 296,865 unselected subjects from the Icelandic population 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Table 8 | Early and late onset cases of pre-eclampsia 
 
 
 
 
Number of cases of early onset and late onset preeclampsia used in data analysis. Only cases where gestational age at diagnosis of 
pre-eclampsia was unequivocally recorded were included in sub-group analysis.  
“EO-preeclampsia” is early onset pre-eclampsia, diagnosed at <34 weeks gestation. “LO-preeclampsia” is late onset pre-eclampsia, 
diagnosed at ≥34 weeks gestation.  
 
 
Cohort EO-preeclampsia LO-preeclampsia 
GOPEC 274 625 
deCODE 176 360 
FINNPEC 123 479 
MoBa 58 1095 
Supplementary Table 9 | Per cohort pedigree counts used for EMIM analysis 
Group MoBa GOPEC FINNPEC Total 
Case Trios 798 0 0 798 
Case Mother-Offspring  Duos 315 953 403 1671 
Case Father-Offspring Duos 9 0 0 9 
Case Mothers* 50 922 326 1298 
Case Fathers* 33 0 0 33 
Case Offspring* 6 51 126 183 
Case Parents
†
 9 0 0 9 
Control Mother-Offspring Duos 429 0 487 916 
Control Father-Offspring Duos 5 0 0 5 
Controls
‡
 1494 5083 383 6960 
 
*Subjects without other family members 
†
Two parents without their case offspring 
‡
Includes parents in control trios 
 
 
Supplementary Figure 1 
 
 
Forest plots for GWAS and replication cohorts at independent variants near FLT1 giving evidence for 
association with preeclampsia. 
Forests plots are presented in order of strength of association with preeclampsia (PE) (see Table 1).  The top 
line of each plot gives variant rs number, position on chromosome 13 (human genome build 19), risk allele (i.e.
allele with higher frequency in cases than controls in the GWAS meta-analysis)and its population frequency in 
parenthesis, other allele, and Phet giving the P value for heterogeneity of odd ratios (OR) in the five cohorts.
Subsequent lines provide a breakdown of results for each GWAS and replication cohort including number of
cases and controls, the allelic case-control OR and its 95% confidence interval (95% CI) and case-control 
association P value.   [META] indicates corresponding meta-analysis results for GWAS cohorts, replication 
cohorts, or GWAS and replication cohorts combined; each meta-analysis allelic OR is represented by a 
“diamond” whose width corresponds to the 95% CI. The first three Forest plots give unconditional logistic
regression results and the last three plots give logistic regression results that condition out the effect of
rs4769613.  The SNP rs11619261 is included here because it is used as a proxy for rs149427560 in the
FINNPEC cohort (see Table 1). 
 
 
Supplementary Figure 2 
Linkage disequilibrium (LD) matrix showing pairwise LD r2 values among all variants near FLT1
selected for follow-up in Replication cohorts. 
LD r2 values were generated by LDlink software (http://analysistools.nci.nih.gov/LDlink) from 1000Genomes 
Phase 3 genotypes for all European populations.  Variants are ordered by chromosomal position and shown in
 
 
relation to FLT1 and POMP.  Intensity of red shading (see colour legend) shows approximate r2 value for each 
variant pair and implies that the 21 follow-up variants define 9 LD “blocks” with high pairwise r2 within each 
block but low pairwise r2 for members of different blocks.   
 
 
Supplementary Figure 3 
rs12050029: Preeclampsia subtype meta-analysis overview. 
Forest plot for preeclampsia (PE) subtypes defined by early and late onset (EO-PE, LO-PE) and by birthweight 
that is small-for-gestational age (SGA-PE) or not (nonSGA-PE).  Case-control comparison shows risk allele G 
is significantly associated with LO-PE (P=1.4x10-5), nonSGA-PE (P=4.5x10-4) and SGA-PE (P=6.6x10-3). The 
strength of association does not differ between SGA-PE and nonSGA-PE. 
 
